Recipient Human Leukocyte Antigen-peptide complex (Recipient pHLA)

Recipient Human Leukocyte Antigen (HLA)-peptide complexes are the fundamental units of immune recognition, consisting of a polymorphic HLA molecule bound to a specific peptide fragment derived from cellular proteins. In the clinical setting of hematopoietic stem cell or organ transplantation, these complexes on recipient cells are recognized as foreign by donor T cells, serving as the primary drivers of Graft-versus-Host Disease (GvHD) and transplant rejection (Nature Reviews Disease Primers, 2017). Beyond transplantation, these complexes are increasingly utilized as highly specific therapeutic targets in oncology, where engineered T-cell receptors (TCRs) or bispecific T-cell engagers are designed to recognize tumor-specific peptides presented by HLA (Nature Reviews Drug Discovery, 2021). The interaction between the T-cell receptor and the HLA-peptide complex determines the specificity and intensity of the immune response (StatPearls, 2023). Therapeutic modulation of this interaction includes the use of immunosuppressants to prevent T-cell activation in transplants and the development of TCR-based biologics, such as Tebentafusp, to induce potent anti-tumor activity (Journal of Clinical Oncology, 2022). Challenges in targeting these complexes include the high degree of HLA polymorphism among individuals and the risk of cross-reactivity with similar peptides in healthy tissues.

Other names

MHC-peptide complexRecipient MHC-peptide complexAlloantigenpMHCHLA-antigen complex

T-cell receptor (TCR) binding and activation, T-cell mediated cytotoxicity, Immunosuppression via signal blockade, and T-cell costimulation inhibition.